Rein Therapeutics Inc. (RNTX)
Automate Your Wheel Strategy on RNTX
With Tiblio's Option Bot, you can configure your own wheel strategy including RNTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RNTX
- Rev/Share 0.0
- Book/Share 2507.3526
- PB 0.0006
- Debt/Equity 0.0
- CurrentRatio 2.3755
- ROIC -0.7587
- MktCap 33452087.0
- FreeCF/Share -1027.5665
- PFCF -1.5007
- PE -0.0008
- Debt/Assets 0.0
- DivYield 0
- ROE -0.7986
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | RNTX | Rodman & Renshaw | -- | Buy | -- | $8 | Jan. 28, 2025 |
News
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders
Published: June 24, 2025 by: PRNewsWire
Sentiment: Neutral
Meeting adjourned to Wednesday, July 23, 2025 at 9:00 a.m. Eastern Time AUSTIN, Texas , June 24, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medications to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it adjourned, without conducting any business, the 2025 annual meeting of stockholders (the "Annual Meeting") on Tuesday, June 24, 2025, due to the fact that a quorum was not achieved and to allow more opportunity for Company stockholders to vote on all proposals described in Rein's definitive proxy statement filed …
Read More
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
AUSTIN, Texas , May 1, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, today announced a collaboration for the integration of Qureight's deep-learning platform into Rein's planned Phase 2 trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis (IPF). Rein previously announced positive topline results from Cohort 2 (5 mg BID) of the Phase 1b clinical trial of …
Read More
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
AUSTIN, Texas , April 28, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that an abstract has been accepted at the American Thoracic Society (ATS) 2025 International Conference taking place May 18-21, 2025 in San Francisco, CA. Details of the poster presentation are as follows: Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three Dimensional (3D) Alveolospheres from IPF and Normal Donor Lung Samples Poster #: P1463 Session: B75 Targeting Cellular Senescence, …
Read More
About Rein Therapeutics Inc. (RNTX)
- IPO Date 2017-06-29
- Website http://www.reintx.com
- Industry Medical - Pharmaceuticals
- CEO James Brian Windsor
- Employees 11